🇺🇸 FDA
Patent

US 11699503

Methods of identifying and treating patient populations amenable to cancer immunotherapy

granted A61KA61K2039/57A61K38/193

Quick answer

US patent 11699503 (Methods of identifying and treating patient populations amenable to cancer immunotherapy) held by The Regents of the University of California expires Mon Jul 06 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue Jul 11 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 06 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
14
CPC classes
A61K, A61K2039/57, A61K38/193, A61K39/395, A61K39/3955